IFNA1 and Hemoglobin C Measurement: Thus, in addition to being a prognostic marker, the differential expression of our new molecular signature could also represent a predictive biomarker of response to immunotherapy, allowing physicians to avoid the toxicity of ineffective treatments for ECM3+/IFN− HGBC patients and to optimize the management of these expensive drugs.